2013
Predictive value of phase I trials for safety and final approved dose in later trials: Analysis of 33,845 patients.
Fontes Jardim D, Hess K, LoRusso P, Kurzrock R, Hong D. Predictive value of phase I trials for safety and final approved dose in later trials: Analysis of 33,845 patients. Journal Of Clinical Oncology 2013, 31: 2509-2509. DOI: 10.1200/jco.2013.31.15_suppl.2509.Peer-Reviewed Original ResearchDose-limiting toxicityMultiple logistic regression analysisDeath rateLater trialsPhase IPhase II doseRelevant side effectsDose of agentDrug Administration websiteLogistic regression analysisChi-squared testAdverse eventsMultivariable analysisSafety profileFinal doseGrade 3Oral drugsNew agentsSide effectsPackage insertsPredictive valueUS FoodRegistration trialsCytotoxic agentsSignificant toxicity
1995
Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents
Corbett T, Valeriote F, Lorusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lowichik N, Biernat L, Foster B, Wozniak A, Lisow L, Valdivieso M, Baker L, Leopold W, Sebolt J, Bissery M, Mattes K, Dzubow J, Rake J, Perni R, Wentland M, Coughlin S, Shaw J, Liversidge G, Liversidge E, Bruno J, Sarpotdar P, Moore R, Patterson G. Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents. Pharmaceutical Biology 1995, 33: 102-122. DOI: 10.3109/13880209509067092.Peer-Reviewed Original ResearchSCID miceNude miceTumor modelHuman tumorsHuman tumor xenograft modelsUnique histologic appearanceXenograft model systemAthymic nude miceHuman tumor modelsUnique biologic entityTumor xenograft modelClass of agentsNormal cellsDrug response profilesActivity testingTumor takeSolid tumor cellsVariety of agentsClinical trialsBiologic behaviorHistologic appearanceNew agentsXenograft modelSingle tumorSolid tumors